ArticleJournal of clinical practice and research2023
The Evaluation of the Role of (Pro)hepcidin in Anemia Encountered in Inflammatory Bowel Diseases.
Article in Journal of clinical practice and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Evaluation of Serum Hepcidin and Fecal Calprotectin for Disease Activity Assessment in Inflammatory Bowel Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hepcidin is a peptide that acts as a hormone that provides iron homeostasis in the body and has antimicrobial activity. The synthesis of hepcidin is stimulated during inflammation and causes inflammation anemia. For this purpose, we aimed to determine the role of (pro)hepcidin in anemia in inflammatory bowel diseases (IBD) and its correlation with clinical and biochemical findings. Materials and Methods: A total of 61 patients, 19 (31.1%) of whom were diagnosed with Crohn's disease (CD), 42 (68.9%) with ulcerative colitis (UC), and a control group of 23 were included. Hepcidin and biochemical parameters which are related to anemia were measured. Results: There was a significant difference between the CD group and vs control group in terms of hepcidin level. As the disease activity increases, the hepcidin level decreases with a probability of 83%. Hepcidin levels were found to be significantly lower in the CD group. Although hepcidin levels were lower in the UC group than in the control group, the result was not statistically significant. Conclusion: We didn't detect a statistically significant difference in the level of hepcidin between IBD and the control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.